Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2/3 1Phase 2 1

Status

Unknown 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Carcinoma, Non-Small-Cell Lung 16Nasopharyngeal Carcinoma 6Colorectal Neoplasms 4Lung Neoplasms 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Neoplasms 2Nasopharyngeal Neoplasms 2Head and Neck Neoplasms 2Squamous Non-small Cell Lung Cancer 1Sarcoma 1Recurrence 1Neuroblastoma 1Meningeal Carcinomatosis 1Melanoma 1Lymphoma, T-Cell 1Locally Advanced Squamous Non-small Cell Lung Cancer 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Carcinoma, Hepatocellular 1Breast Cancer Organoids 1Advanced Pancreatic Cancer 1Adenoviridae Infections 1Adenocarcinoma of Lung 1

Interventions

Cisplatin 38Carboplatin 28Gemcitabine 23Docetaxel 20Radiotherapy 18Etoposide 15Paclitaxel 13Erlotinib Hydrochloride 13Vinorelbine 11Drug Therapy 11pembrolizumab 9aumolertinib 9apatinib 9Pemetrexed 9Gefitinib 9osimertinib 7endostar protein 7Thoracic Surgery, Video-Assisted 7Blood Specimen Collection 7camrelizumab 6anlotinib 6Vinblastine 6Surgical Procedures, Operative 6sintilimab 5Radiosurgery 5Fluorodeoxyglucose F18 5Cyclophosphamide 5Bevacizumab 5durvalumab 4Mitomycin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × Lung Neoplasms × Endostatins × Clear all
NCT04613284 2020-11-03

RELIEF

Shanghai Chest Hospital

Phase 4 Unknown
97 enrolled
Thoracic

Lung Neoplasms

NCT02375022 2015-03-24

Rh-Endostatin in Combination With Icotinib for Advanced NSCLC With EGFR Mutations

Zhejiang University

Phase 2 Unknown
10 enrolled
Thoracic

Lung Neoplasms

NCT02350361 2015-01-29

Endostar Combination With Chemotherapy and EGFR-TKI in Lung Cancer Rechallenging Treatment After Acquired Resistance.

Peking University Third Hospital

Phase 2/3 Unknown
60 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡